Granulomatous lung disease occurring during etanercept treatment.
Phillips
Kristine
K
Brigham and Women's Hospital, Boston, Massachussetts 02115, USA.
Weinblatt
Michael
M
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D000068800:Etanercept; D006105:Granulomatous Disease, Chronic / Q000139:chemically induced*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007155:Immunologic Factors / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept